Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the clinical trial milestones, cash-runway estimates, and dilution risks hidden inside Adaptimmune’s dense disclosures can feel like analyzing lab results without a microscope. Our dedicated SEC page solves that problem by turning every page—whether a 300-page 10-K or a same-day 8-K—into a clear narrative. If you have ever searched for Adaptimmune Therapeutics SEC filings explained simply, you are in the right place.
Stock Titan’s AI reads each document the moment it reaches EDGAR, then serves concise summaries, red-flag alerts, and side-by-side comparisons. Need the next Adaptimmune Therapeutics quarterly earnings report 10-Q filing? It appears here in real time with an Adaptimmune Therapeutics earnings report filing analysis that highlights R&D burn and partnership revenue shifts. Curious about executive confidence? We tag every Adaptimmune Therapeutics Form 4 insider transactions real-time entry, making it effortless to track Adaptimmune Therapeutics executive stock transactions Form 4 before headlines break.
Our coverage spans every filing type investors rely on:
- Adaptimmune Therapeutics annual report 10-K simplified—spot pipeline progress and cash runway in minutes.
- Adaptimmune Therapeutics 8-K material events explained—follow trial pauses, partnership updates, or financings as they post.
- Adaptimmune Therapeutics proxy statement executive compensation—understand incentive alignment without decoding legalese.
- Adaptimmune Therapeutics insider trading Form 4 transactions—monitor insider buying or selling patterns instantly.
Whether you are understanding Adaptimmune Therapeutics SEC documents with AI for a trade idea or building a long-term oncology thesis, our platform equips you to act quickly and confidently. Complex cell-therapy disclosures clarified—no biotech PhD required.
Christopher James Hill, identified as Chief Financial Officer and a director of Adaptimmune Therapeutics PLC (ADAP), filed an Initial Form 3 reporting that he does not beneficially own any securities of the issuer as of the event date 09/10/2025. The filing is signed 10/08/2025 and lists the reporter's business address in Abingdon, UK. No non-derivative or derivative holdings are disclosed on the form.
Adaptimmune insider sale by CFO Gavin Wood: The Form 4 shows that Gavin Wood, Chief Financial Officer and director of Adaptimmune Therapeutics plc (ADAP), sold the equivalent of 96,000 ordinary shares on 09/02/2025. Those shares were represented by 16,000 ADSs, each ADS equal to six ordinary shares, and were sold at $0.0594 per ADS (reported as $0.0099 per ordinary share). After this transaction the reporting person holds 0 ADSs but retains nominal cost and other options covering 11,140,760 ordinary shares of the issuer.
Form 144 notice for Adaptimmune Therapeutics plc (ADAP) reports a proposed sale of 16,000 American Depositary Shares (ADS) with an aggregate market value of $942.40, to be sold on or about 09/02/2025 on Nasdaq. The filing shows the ADS were acquired in three open-market purchases: 5,500 on 06/29/2020, 4,000 on 12/14/2020, and 6,500 on 05/20/2022, all paid in cash. The filing states there were no securities sold in the past three months by the selling person. Several identifying fields for the filer and issuer (names, CIK) are blank in the provided content.
Adaptimmune Therapeutics plc reporting person William C. Bertrand, Jr., who is Chief Operating Officer and a director, disclosed the sale of 207,000 ordinary shares (represented by 34,500 ADSs) on 08/28/2025 at an ADS sale price of $0.0603 (equivalent to $0.01005 per ordinary share). After the reported sale he beneficially owns 986,352 ordinary shares (164,392 ADSs). The filing states he also holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares. The Form 4 is signed 08/29/2025 and indicates the securities sold were ADSs representing ordinary shares.
Adaptimmune Therapeutics plc (ADAP) Form 144 notice reports a proposed sale of 34,500 American Depositary Shares (ADS) executed through ETrade by Morgan Stanley with an approximate sale date of 08/28/2025 on Nasdaq. The filing shows an aggregate market value of $2,070 for the shares and lists 256,032,610 shares outstanding. The securities were acquired in an open-market purchase on 12/14/2020 for cash by the person filing, and no securities were reported sold in the prior three months. Several filer and issuer identification fields in the document are left blank in the provided content.
Adaptimmune Therapeutics plc disclosed a Second Variation Letter Agreement affecting the share options of Mr. Wood. Under the revised terms, registered awards will continue to vest until a Revised Termination Date in line with the Plan rules and their original vesting schedules. Mr. Wood is allowed a 12‑month period from that Revised Termination Date to exercise any Market Value Options that have vested by then. The filing states that the summary is qualified by the full agreement filed as Exhibit 10.1 to the Current Report.
Adaptimmune insider sales by a director reduced his indirect holdings to zero. Ali Behbahani, a director and manager of entities holding shares, reported two dispositions of Adaptimmune ordinary shares represented by ADSs. On 08/15/2025 he reported sale of 4,828,206 ordinary shares at a weighted average price of $0.011 per share, leaving 14,671,794 shares indirectly owned. On 08/18/2025 he reported sale of 14,671,794 ordinary shares at a weighted average price of $0.012 per share, resulting in zero indirect beneficial ownership. The filings state these ordinary shares were held as ADSs by NEA 16 and explain price ranges and ownership through NEA entities.
This Amendment No. 3 to the Schedule 13D updates prior filings by New Enterprise Associates-related reporting persons concerning Adaptimmune Therapeutics Plc ordinary shares. Collectively the reporting persons hold 4 Ordinary Shares (the "Firm Shares"), which the filing states represents 0% of the class based on 1,590,309,546 Ordinary Shares outstanding. The filing discloses shared voting and dispositive power over those 4 shares and identifies the funds, control entities and individual managers involved. The Amendment attaches Schedule A for recent transactions and cites Exhibit 1 (joint filing agreement) and Exhibit 3 (power of attorney).
FAQ
What is the current stock price of Adaptimmune Therapeutics Plc (ADAP)?
What is the market cap of Adaptimmune Therapeutics Plc (ADAP)?
